Bone problems: latest news

Bone problems resources

  • Longer-term side-effects

    Effective HIV treatment has significantly reduced the risk of serious kidney disease in people with HIV. However, most anti-HIV drugs can cause some damage to the kidneys, so...

    From: Booklets

    Information level Level 2
  • Other tests

    Blood pressure is the force that the beating heart causes in the arteries, veins, and blood vessels that carry blood around the body. Blood pressure is measured...

    From: Booklets

    Information level Level 2
  • Side effects

    The most common side effects are the result of your body getting used to a new drug. After a few weeks, these side effects usually...

    From: The basics

    Information level Level 1
  • HIV treatment, metabolic changes and ageing

    Anti-HIV drugs can cause changes inside your body, known as metabolic changes. These can include: changes to blood fats (also called lipids), such as having too much low-density (LDL, or...

    From: Booklets

    Information level Level 2
  • Bone loss

    Osteoporosis has traditionally been a disease affecting women past the age of menopause. However, studies have established that osteoporosis is also common amongst HIV-positive men...

    From: HIV treatments directory

    Information level Level 4
  • Osteonecrosis

    Osteonecrosis, literally 'bone death', is caused by poor blood supply to an area of bone. Like the other bone disorder osteoporosis, osteonecrosis has only recently...

    From: HIV treatments directory

    Information level Level 4
  • Osteoporosis and osteopenia

    Osteoporosis is a condition where the bones lose mass and density. It is commonly referred to as 'thinning of the bones' and occurs most commonly...

    From: HIV treatments directory

    Information level Level 4

Bone problems features

Bone problems news from aidsmap

More news

Bone problems news selected from other sources

  • Fearing Drugs’ Rare Side Effects, Millions Take Their Chances With Osteoporosis

    Millions of Americans are missing out on a chance to avoid debilitating fractures from weakened bones, researchers say, because they are terrified of exceedingly rare side effects from drugs that can help them.

    02 June 2016 | New York Times
  • A question of timing: A lawsuit claims Gilead Sciences could have developed a less-harmful version of its HIV treatment sooner

    More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the company’s key HIV medicine that was less toxic to kidneys and bones. But in 2004 Gilead executives stopped the research, only to restart it as the expiration of tenofovir’s patent in 2018 neared.

    30 May 2016 | Los Angeles Times
  • HIV-infected young males have higher rates of bone loss than females

    Accumulating evidence suggests that rates of low bone mass are greater in HIV-infected males than in females. Researchers led by Grace Aldrovandi, MD, chief of the Division of Infectious Diseases at Children's Hospital Los Angeles, studied 11 biomarkers associated with inflammation, bone loss and/or bone formation in about 450 individuals -- assessed by sex and HIV status -- to try to determine causes of this differential bone loss.

    11 March 2016 | Eurekalert Medicine & Health
  • Free new tool for health providers to assist physical rehabilitation in people living with HIV

    The free website, entitled "How Rehabilitation Can Help People Living with HIV in Sub-Saharan Africa: An Evidence-Informed Tool for Rehab Providers", was adapted from a Canadian resource and is also downloadable for use on paper. It's designed to be a one-stop resource for physiotherapists, occupational therapists and other health workers who can quickly and easily research the most common HIV-related disabilities, and find evidence-based rehabilitation solutions

    02 December 2015 | Eurekalert Medicine & Health
  • TAF and TDF Compared for Kidney, Bone Toxicity in Black HIV+ Patients

    Including tenofovir alafenamide (TAF) in single-tablet elvitegravir/cobicistat/emtricitabine (E/C/F/TAF) is associated with reduced renal and bone toxicity compared to tenofovir disoproxil fumarate (TDF)-containing single-tablet (E/C/F/TDF) therapy, according to an analysis of data from two Phase 3 trials, reported at IDWeek 2015.

    12 October 2015 | Monthly Prescribing Reference
  • HIV Increases Bone Fracture Risk by 32% in Middle-Aged U.S. Women

    HIV infection inflated the risk of a new fracture 32% in a mostly premenopausal group in the Women's Interagency HIV Study (WIHS). Older age, white race, previous fracture history, injection drug use, opiate use and smoking also independently raised the risk of any fracture in multivariate analysis.

    05 October 2015 | The Body
  • Tenofovir Alafenamide Combo Pill Matches Truvada for HIV Efficacy, but Easier on Bones and Kidneys

    A fixed-dose combination pill containing tenofovir alafenamide (TAF) worked as well in a Phase 3 trial as the current Truvada pill containing the older tenofovir disoproxil fumarate (TDF) -- which is used for both HIV treatment and pre-exposure prophylaxis or PrEP -- but causes less kidney and bone toxicity, according to an announcement this week from Gilead Sciences.

    04 September 2015 | HIVandHepatitis.com
  • ART: Daily Vitamin D and Calcium Stave Off Bone Loss

    Patients with HIV infection who take antiretroviral therapy (ART) can also reduce antiretroviral therapy-related bone loss by 50% by taking daily high-dose vitamin D and calcium supplements, according to a 48-week study.

    17 June 2015 | Medscape
  • The puzzle of thin bones in young MSM

    In Amsterdam, researchers have established a large cohort, called AGEhIV, of both HIV-positive and HIV-negative people of similar age and risk behaviours. Young MSM in this study, regardless of HIV infection, were surprisingly at risk for having thinner-than-normal bones.

    01 October 2014 | CATIE
  • Gilead Sciences: A Preview of Important HIV Drug Study Results

    Gilead is running nine phase III studies involving tenofovir alafenamide (TAF), which reflects the importance of the drug to Gilead's future HIV business. It is collecting an enormous amount of clinical data in which to make the case that TAF should be a preferred backbone drug for new and existing HIV patients, as well as patients who cannot use Viread because of pre-existing kidney conditions.

    23 September 2014 | The Street
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also